Abigail “Abbey” L. Jenkins is an experienced biopharmaceutical executive and board director with more than 25 years of leadership across public and private biotech and pharmaceutical companies. She has a proven track record of building and leading organizations through strategic transformations—including growth, business reshaping, and the pursuit of strategic alternatives—along with commercialization and value creation, having successfully launched six products and raised more than $250 million in capital across her career.  Ms. Jenkins is currently the CEO of a Stealth Mode Biotech developing novel therapies for patients with cancer.  She previously served as President, Chief Executive Officer, and a member of the Board of Directors of Gamida Cell, Ltd. (NASDAQ: GMDA), a pioneer in cell therapies for patients with blood cancers. During her tenure, she led the company through the FDA approval and launch of Omisirge®, the first-ever allogeneic hematopoietic stem cell donor source approved in the United States. Prior to Gamida Cell, she was Chief Commercial and Business Officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy, and portfolio management functions across multiple therapeutic areas. Earlier in her career, Ms. Jenkins served as Chief Commercial and Business Officer at Lyndra Therapeutics, Senior Vice President and Business Unit Head of Vaccines at Emergent BioSolutions (NYSE: EBS), as Chief Commercial Officer and U.S. Business Head at Aquinox Pharmaceuticals (NASDAQ: AQXP). She has also held senior commercial and business development roles at Relypsa, Actavis (now Teva Pharmaceuticals), MedImmune (now AstraZeneca), and Pfizer.  Ms. Jenkins currently serves on the Board of Directors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) and previously served on the Board of Directors of XORTX Therapeutics, Inc. (NASDAQ: XRTX). She is also Chair of the Editorial Board of the Biotech CEO Sisterhood. She holds a Master of Science in Biotechnology and Biotechnology Business Enterprise from The Johns Hopkins University, a Bachelor of Arts in Psychology and Biology from Indiana University, and a Certificate of Achievement in General Management as a Kellogg Executive Scholar. In 2022, she was recognized as a PharmaVoice 100 honoree in the Disrupter category, honoring the industry’s most inspiring and impactful leaders.  Our Board believes that Ms. Jenkins’ extensive experience in the commercialization of pharmaceutical products, her business development and corporate strategy expertise and her experience on the boards of public companies and in senior leadership roles across several biopharmaceutical companies qualifies her to serve on our Board of Directors.